Rain Lei — Projects Portfolio

eClinicalMedicine (The Lancet) · 2024eClinicalMedicine (柳叶刀) · 2024

NORA Study — Final Overall Survival AnalysisNORA 研究 — 最终总生存期分析

• Maintenance niraparib demonstrated a numerically favourable OS benefit over placebo in PSROC (median OS: 51.5 vs 47.6 months; HR=0.86, 95% CI: 0.60–1.23; not statistically significant; study not powered for OS)维持治疗尼拉帕利在 PSROC 中展现数值上有利的 OS 获益（中位 OS：51.5 vs 47.6 个月；HR=0.86，95% CI：0.60–1.23；未达统计学显著；研究非以 OS 为效力终点）
• OS benefit consistent irrespective of gBRCA status (gBRCAmut: HR=0.86; gBRCAwt: HR=0.87). Manageable safety; median follow-up 57.9 months (N=265)OS 获益不受 gBRCA 状态影响（gBRCAmut：HR=0.86；gBRCAwt：HR=0.87）。安全性可控；中位随访 57.9 个月（N=265）

Therapeutics and Clinical Risk Management · 2025Therapeutics and Clinical Risk Management · 2025

ANNIE Study — Adverse Event Management in PROCANNIE 研究 — 铂耐药卵巢癌不良事件管理

• Niraparib + anlotinib demonstrated antitumor activity in PROC with ORR 50% (1 CR + 19 PR), median PFS 9.2 months, and updated median OS 18.2 months (95% CI: 12.1–NE)尼拉帕利+安罗替尼在 PROC 中展现抗肿瘤活性：ORR 50%（1 CR + 19 PR），中位 PFS 9.2 个月，更新中位 OS 18.2 个月（95% CI：12.1–NE）
• Common TEAEs: hypertension (55%), thrombocytopenia (38%), neutropenia (35%). Dose modifications maintained efficacy with acceptable tolerability常见 TEAE：高血压（55%）、血小板减少（38%）、中性粒细胞减少（35%）。剂量调整维持疗效，耐受性可接受

ASCO 2023 · Poster #5562ASCO 2023 · 壁报 #5562

PRIME Study — Niraparib in Advanced OC with MRDPRIME 研究 — 尼拉帕利用于伴有残余病灶的晚期卵巢癌

• Maintenance niraparib demonstrated additional antitumor activity over placebo in patients with MRD post first-line chemotherapy (ORR: 57.4% vs 30.8%; OR=3.2, 95% CI: 1.11–9.11)维持治疗尼拉帕利在一线化疗后 MRD 患者中较安慰剂展现额外抗肿瘤活性（ORR：57.4% vs 30.8%；OR=3.2，95% CI：1.11–9.11）
• Niraparib significantly prolonged PFS over placebo (median PFS: 22.3 vs 8.3 months; HR=0.36, 95% CI: 0.19–0.71), supporting dual maintenance and treatment role in MRD尼拉帕利较安慰剂显著延长 PFS（中位 PFS：22.3 vs 8.3 个月；HR=0.36，95% CI：0.19–0.71），支持在 MRD 中兼具维持和治疗的双重角色

ESMO 2024 · Abstract #29PESMO 2024 · 摘要 #29P

Real-World Safety of Osimertinib in Chinese NSCLC Patients奥希替尼在中国非小细胞肺癌患者中的真实世界安全性

• First-line osimertinib was well-tolerated in EGFRm advanced NSCLC (N=1,700): any-grade AEs 71.7%, grade ≥3 AEs 11.6%, discontinuation due to AEs 4.6%一线奥希替尼在 EGFRm 晚期 NSCLC 中耐受性良好（N=1,700）：任意级别 AE 71.7%，≥3 级 AE 11.6%，因 AE 停药 4.6%
• No new safety signals identified; safety profile consistent with FLAURA and AURA3 pivotal trials, confirming real-world applicability in Chinese population未发现新安全信号；安全性与 FLAURA 和 AURA3 关键试验一致，证实在中国人群中的真实世界适用性

TiO₂-Deposited Biosilica for Wastewater TreatmentTiO₂ 沉积生物硅石用于废水处理

National University of Singapore新加坡国立大学

Developed a green, carbon-neutral dye degradation method by functionalizing biosilica from marine diatoms with TiO₂ nanoparticles, enhancing photocatalytic efficiency by ~25%.开发绿色碳中和染料降解方法，将海洋硅藻生物硅石与 TiO₂ 纳米粒子功能化，光催化效率提升约 25%。

Functional Characterization of Kinesin Cin8p in Yeast Models酵母模型中驱动蛋白 Cin8p 的功能表征

University of California, Berkeley加州大学伯克利分校

Investigated interspecies differences in spindle dynamics by cross-expressing S. cerevisiae Cin8p in C. thermophilum, using gene cloning and site-directed mutagenesis for functional analysis.通过在不同酵母种间交叉表达 Cin8p 驱动蛋白研究纺锤体动力学差异，利用基因克隆和定点突变进行功能分析。